124 results on '"Abood ME"'
Search Results
2. Significance of cannabinoid CB1 receptors in improgan antinociception.
- Author
-
Gehani NC, Nalwalk JW, Razdan RK, Martin BR, Sun X, Wentland M, Abood ME, Hough LB, Gehani, Neal C, Nalwalk, Julia W, Razdan, Raj K, Martin, Billy R, Sun, Xufung, Wentland, Mark, Abood, Mary E, and Hough, Lindsay B
- Abstract
Unlabelled: Improgan is a congener of the H(2) antagonist cimetidine, which produces potent antinociception. Because a) the mechanism of action of improgan remains unknown and b) this drug may indirectly activate cannabinoid CB(1) receptors, the effects of the CB(1) antagonist/inverse agonist rimonabant (SR141716A) and 3 congeners with varying CB(1) potencies were studied on improgan antinociception after intracerebroventricular (icv) dosing in rats. Consistent with blockade of brain CB(1) receptors, rimonabant (K(d) = 0.23 nM), and O-1691 (K(d) = 0.22 nM) inhibited improgan antinociception by 48% and 70% after icv doses of 43 nmol and 25 nmol, respectively. However, 2 other derivatives with much lower CB(1) affinity (O-1876, K(d) = 139 nM and O-848, K(d) = 352 nM) unexpectedly blocked improgan antinociception by 65% and 50% after icv doses of 300 nmol and 30 nmol, respectively. These derivatives have 600-fold to 1500-fold lower CB(1) potencies than that of rimonabant, yet they retained improgan antagonist activity in vivo. In vitro dose-response curves with (35)S-GTPgammaS on CB(1) receptor-containing membranes confirmed the approximate relative potency of the derivatives at the CB(1) receptor. Although antagonism of improgan antinociception by rimonabant has previously implicated a mechanistic role for the CB(1) receptor, current findings with rimonabant congeners suggest that receptors other than, or in addition to CB(1) may participate in the pain-relieving mechanisms activated by this drug. The use of congeners such as O-848, which lack relevant CB(1)-blocking properties, will help to identify these cannabinoid-like, non-CB(1) mechanisms.Perspective: This article describes new pharmacological characteristics of improgan, a pain-relieving drug that acts by an unknown mechanism. Improgan may use a marijuana-like (cannabinoid) pain-relieving mechanism, but it is shown presently that the principal cannabinoid receptor in the brain (CB(1)) is not solely responsible for improgan analgesia. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
3. The NPXXY Motif Regulates β-Arrestin Recruitment by the CB1 Cannabinoid Receptor.
- Author
-
Leo LM, Al-Zoubi R, Hurst DP, Stephan AP, Zhao P, Tilley DG, Miess E, Schulz S, Abood ME, and Reggio PH
- Subjects
- Humans, beta-Arrestins metabolism, Cannabinoids, GTP-Binding Proteins metabolism, HEK293 Cells, Receptors, G-Protein-Coupled genetics, Receptors, G-Protein-Coupled metabolism, beta-Arrestin 1 genetics, beta-Arrestin 1 metabolism, Receptor, Cannabinoid, CB1 genetics, Receptor, Cannabinoid, CB1 metabolism
- Abstract
Background: Activation of signaling effectors by G-protein coupled receptors (GPCRs) depends on different molecular mechanisms triggered by conserved amino acid residues. Although studies have focused on the G-protein signaling state, the mechanism for β-arrestin signaling by CB1 is not yet well defined. Studies have indicated that transmembrane helix 7 (TMH7) and the highly conserved NPXXY motif can be subject to different conformational changes in response to biased ligands and could therefore participate in a molecular mechanism to trigger β-arrestin recruitment. Objective: To investigate the effect of mutations in the NPXXY motif on different signaling pathways activated by the CB1 receptor. Materials and Methods: Point mutations of the NPXXY motif and associated residues were generated in the CB1 receptor using site-directed mutagenesis and transfection into HEK-293 cells. Signaling by wild-type and mutant receptors was analyzed by quantifying inhibition of cAMP, and by β-arrestin recruitment assays. Results: We found that N7.49 and Y7.53 are essential for β-arrestin recruitment by CB1. N7.49A and Y7.53F impair β-arrestin signaling, with no effect on G-protein signaling. We found a regulatory role for residue I2.43; I2.43 interacts with Y7.53, affecting its positioning. Reducing steric bulk at I2.43 (I2.43A) enhances β-arrestin1 recruitment, while introducing a polar residue (I2.43T) reduces β-arrestin recruitment. Conclusions: These findings point to a novel mechanism for β-arrestin recruitment, implicating amino acids in the NPXXY motif as critical for the putative β-arrestin biased conformational state of Class A GPCRs.
- Published
- 2023
- Full Text
- View/download PDF
4. Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure-Activity Relationship.
- Author
-
Figuerola-Asencio L, Morales P, Zhao P, Hurst DP, Sayed SS, Colón KL, Gómez-Cañas M, Fernández-Ruiz J, Croatt MP, Reggio PH, Abood ME, and Jagerovic N
- Abstract
GPR55 is an orphan G-protein coupled receptor involved in various pathophysiological conditions. However, there are only a few noncannabinoid GPR55 ligands reported so far. The lack of potent and selective GPR55 ligands precludes a deep exploration of this receptor. The studies presented here focused on a thienopyrimidine scaffold based on the GPR55 antagonist ML192, previously discovered by high-throughput screening. The GPR55 activities of the new synthesized compounds were assessed using β-arrestin recruitment assays in Chinese hamster ovary cells overexpressing human GPR55. Some derivatives were identified as GPR55 antagonists with functional efficacy and selectivity versus CB1 and CB2 cannabinoid receptors., Competing Interests: The authors declare no competing financial interest., (© 2022 The Authors. Published by American Chemical Society.)
- Published
- 2022
- Full Text
- View/download PDF
5. Anti-Inflammatory Properties of KLS-13019: a Novel GPR55 Antagonist for Dorsal Root Ganglion and Hippocampal Cultures.
- Author
-
Brenneman DE, Kinney WA, McDonnell ME, Zhao P, Abood ME, and Ward SJ
- Subjects
- Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents therapeutic use, Ganglia, Spinal metabolism, Hippocampus metabolism, Humans, NLR Family, Pyrin Domain-Containing 3 Protein, Paclitaxel pharmacology, Receptors, Cannabinoid metabolism, Cannabinoids therapeutic use, Neuralgia drug therapy
- Abstract
KLS-13019, a novel devised cannabinoid-like compound, was explored for anti-inflammatory actions in dorsal root ganglion cultures relevant to chemotherapy-induced peripheral neuropathy (CIPN). Time course studies with 3 µM paclitaxel indicated > 1.9-fold increases in immunoreactive (IR) area for cell body GPR55 after 30 min as determined by high content imaging. To test for reversibility of paclitaxel-induced increases in GPR55, cultures were treated for 8 h with paclitaxel alone and then a dose response to KLS-13019 added for another 16 h. This "reversal" paradigm indicated established increases in cell body GPR55 IR areas were decreased back to control levels. Because GPR55 had previously reported inflammatory actions, IL-1β and NLRP3 (inflammasome-3 marker) were also measured in the "reversal" paradigm. Significant increases in all inflammatory markers were produced after 8 h of paclitaxel treatment alone that were reversed to control levels with KLS-13019 treatment. Accompanying studies using alamar blue indicated that decreased cellular viability produced by paclitaxel treatment was reverted back to control levels by KLS-13019. Similar studies conducted with lysophosphatidylinositol (GPR55 agonist) in DRG or hippocampal cultures demonstrated significant increases in neuritic GPR55, NLRP3 and IL-1β areas that were reversed to control levels with KLS-13019 treatment. Studies with a human GPR55-β-arrestin assay in Discover X cells indicated that KLS-13019 was an antagonist without agonist activity. These studies indicated that KLS-13019 has anti-inflammatory properties mediated through GPR55 antagonist actions. Together with previous studies, KLS-13019 is a potent neuroprotective, anti-inflammatory cannabinoid with therapeutic potential for high efficacy treatment of neuropathic pain., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
6. Cannabinoid Cancer Biology and Prevention.
- Author
-
McAllister SD, Abood ME, Califano J, and Guzmán M
- Subjects
- Biology, Clinical Trials as Topic, Humans, Cannabinoids pharmacology, Medical Marijuana, Neoplasms drug therapy, Neoplasms prevention & control
- Abstract
Plant-based, synthetic, and endogenous cannabinoids have been shown to control a diverse array of biological processes, including regulation of cell fate across cancers. Their promise as broad-based antitumor agents in preclinical models has led to the initiation of pilot clinical trials. Session 5 of the National Cancer Institute's Cannabis, Cannabinoids and Cancer Research Symposium provides an overview of this research topic. Overall, the presentations highlight cannabinoid signal transduction and specific molecular mechanisms underlying cannabinoid antitumor activity. They also demonstrate the broad-based antitumor activity of the plant-based, synthetic, and endogenous cannabinoid compounds. Importantly, evidence is presented demonstrating when cannabinoids may be contraindicated as a treatment for cancer, as in the case of human papilloma virus-meditated oropharynx cancer or potentially other p38 MAPK pathway-driven cancers. Finally, it is discussed that a key to advancing cannabinoids into the clinic is to conduct well-designed, large-scale clinical trials to determine whether cannabinoids are effective antitumor agents in cancer patients., (© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
7. CB1 Cannabinoid Receptor Signaling and Biased Signaling.
- Author
-
Leo LM and Abood ME
- Subjects
- Allosteric Site, Central Nervous System metabolism, Humans, Indoles chemistry, Ligands, Models, Molecular, Piperidines chemistry, Pregnenolone chemistry, Protein Binding, Protein Conformation, Signal Transduction, Cannabinoid Receptor Agonists chemistry, Receptor, Cannabinoid, CB1 chemistry
- Abstract
The CB1 cannabinoid receptor is a G-protein coupled receptor highly expressed throughout the central nervous system that is a promising target for the treatment of various disorders, including anxiety, pain, and neurodegeneration. Despite the wide therapeutic potential of CB1, the development of drug candidates is hindered by adverse effects, rapid tolerance development, and abuse potential. Ligands that produce biased signaling-the preferential activation of a signaling transducer in detriment of another-have been proposed as a strategy to dissociate therapeutic and adverse effects for a variety of G-protein coupled receptors. However, biased signaling at the CB1 receptor is poorly understood due to a lack of strongly biased agonists. Here, we review studies that have investigated the biased signaling profile of classical cannabinoid agonists and allosteric ligands, searching for a potential therapeutic advantage of CB1 biased signaling in different pathological states. Agonist and antagonist bound structures of CB1 and proposed mechanisms of action of biased allosteric modulators are used to discuss a putative molecular mechanism for CB1 receptor activation and biased signaling. Current studies suggest that allosteric binding sites on CB1 can be explored to yield biased ligands that favor or hinder conformational changes important for biased signaling.
- Published
- 2021
- Full Text
- View/download PDF
8. Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy.
- Author
-
Garai S, Leo LM, Szczesniak AM, Hurst DP, Schaffer PC, Zagzoog A, Black T, Deschamps JR, Miess E, Schulz S, Janero DR, Straiker A, Pertwee RG, Abood ME, Kelly MEM, Reggio PH, Laprairie RB, and Thakur GA
- Subjects
- Allosteric Site, Animals, CHO Cells, Cannabinoid Receptor Agonists chemical synthesis, Cannabinoid Receptor Agonists metabolism, Cricetulus, HEK293 Cells, Hippocampus cytology, Humans, Indoles chemical synthesis, Indoles metabolism, Intraocular Pressure drug effects, Ligands, Male, Mice, Inbred C57BL, Molecular Conformation, Molecular Docking Simulation, Molecular Dynamics Simulation, Neurons drug effects, Receptor, Cannabinoid, CB1 chemistry, Receptor, Cannabinoid, CB1 metabolism, Stereoisomerism, Structure-Activity Relationship, Mice, Cannabinoid Receptor Agonists therapeutic use, Glaucoma drug therapy, Indoles therapeutic use, Receptor, Cannabinoid, CB1 agonists
- Abstract
We apply the magic methyl effect to improve the potency/efficacy of GAT211, the prototypic 2-phenylindole-based cannabinoid type-1 receptor (CB1R) agonist-positive allosteric modulator (ago-PAM). Introducing a methyl group at the α-position of nitro group generated two diastereomers, the greater potency and efficacy of erythro , (±)- 9 vs threo , (±)- 10 constitutes the first demonstration of diastereoselective CB1R-allosteric modulator interaction. Of the (±)- 9 enantiomers, (-)-( S , R )- 13 evidenced improved potency over GAT211 as a CB1R ago-PAM, whereas (+)-( R , S )- 14 was a CB1R allosteric agonist biased toward G protein- vs β-arrestin1/2-dependent signaling. (-)-( S , R )- 13 and (+)-( R , S )- 14 were devoid of undesirable side effects (triad test), and (+)-( R , S )- 14 reduced intraocular pressure with an unprecedentedly long duration of action in a murine glaucoma model. (-)-( S , R )- 13 docked into both a CB1R extracellular PAM and intracellular allosteric-agonist site(s), whereas (+)-( R , S )- 14 preferentially engaged only the latter. Exploiting G-protein biased CB1R-allosteric modulation can offer safer therapeutic candidates for glaucoma and, potentially, other diseases.
- Published
- 2021
- Full Text
- View/download PDF
9. Therapeutic Exploitation of GPR18: Beyond the Cannabinoids?
- Author
-
Morales P, Lago-Fernandez A, Hurst DP, Sotudeh N, Brailoiu E, Reggio PH, Abood ME, and Jagerovic N
- Subjects
- Drug Design, Humans, Protein Conformation, Receptors, G-Protein-Coupled chemistry, Receptors, G-Protein-Coupled therapeutic use, Cannabinoids metabolism, Receptors, G-Protein-Coupled metabolism
- Abstract
GPR18 is a G-protein-coupled receptor that belongs to the orphan class A family. Even though it shares low sequence homology with the cannabinoid receptors CB
1 R and CB2 R, a growing body of research suggests its relationship with the endocannabinoid system, not only because it is able to recognize cannabinoid ligands but also because of its expression and ability to heteromerize with CBRs. In this review, we aim to analyze the biological relevance, reported modulators, and structural features of GPR18. In order to guide future drug design in this field, highlights from molecular modeling of GPR18 will be provided.- Published
- 2020
- Full Text
- View/download PDF
10. Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators.
- Author
-
Garai S, Kulkarni PM, Schaffer PC, Leo LM, Brandt AL, Zagzoog A, Black T, Lin X, Hurst DP, Janero DR, Abood ME, Zimmowitch A, Straiker A, Pertwee RG, Kelly M, Szczesniak AM, Denovan-Wright EM, Mackie K, Hohmann AG, Reggio PH, Laprairie RB, and Thakur GA
- Subjects
- Allosteric Regulation drug effects, Animals, Anti-Inflammatory Agents, Non-Steroidal pharmacokinetics, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Biotransformation, Freund's Adjuvant, HEK293 Cells, Humans, Indoles pharmacokinetics, Indoles pharmacology, Inflammation chemically induced, Inflammation prevention & control, Male, Mice, Mice, Inbred C57BL, Neurons drug effects, Receptor, Cannabinoid, CB1 agonists, Stereoisomerism, Structure-Activity Relationship, Anti-Inflammatory Agents, Non-Steroidal chemical synthesis, Fluorine chemistry, Indoles chemistry, Nitrogen chemistry, Receptor, Cannabinoid, CB1 drug effects
- Abstract
Cannabinoid 1 receptor (CB1R) allosteric ligands hold a far-reaching therapeutic promise. We report the application of fluoro- and nitrogen-walk approaches to enhance the drug-like properties of GAT211, a prototype CB1R allosteric agonist-positive allosteric modulator (ago-PAM). Several analogs exhibited improved functional potency (cAMP, β-arrestin 2), metabolic stability, and aqueous solubility. Two key analogs, GAT591 ( 6r ) and GAT593 ( 6s ), exhibited augmented allosteric-agonist and PAM activities in neuronal cultures, improved metabolic stability, and enhanced orthosteric agonist binding (CP55,940). Both analogs also exhibited good analgesic potency in the CFA inflammatory-pain model with longer duration of action over GAT211 while being devoid of adverse cannabimimetic effects. Another analog, GAT592 ( 9j ), exhibited moderate ago-PAM potency and improved aqueous solubility with therapeutic reduction of intraocular pressure in murine glaucoma models. The SAR findings and the enhanced allosteric activity in this class of allosteric modulators were accounted for in our recently developed computational model for CB1R allosteric activation and positive allosteric modulation.
- Published
- 2020
- Full Text
- View/download PDF
11. Acute cocaine administration alters permeability of blood-brain barrier in freely-moving rats- Evidence using miniaturized fluorescence microscopy.
- Author
-
Barr JL, Brailoiu GC, Abood ME, Rawls SM, Unterwald EM, and Brailoiu E
- Subjects
- Animals, Blood-Brain Barrier physiopathology, Brain blood supply, Brain diagnostic imaging, Endothelial Cells drug effects, Fluorescein, Male, Rats, Blood-Brain Barrier drug effects, Capillary Permeability drug effects, Cocaine pharmacokinetics, Microscopy, Fluorescence
- Abstract
Background: Cocaine has a variety of negative effects on the central nervous system, including reports of decreased barrier function of brain microvascular endothelial cells. However, few studies have directly shown the effects of cocaine on blood-brain barrier (BBB) function in vivo. The miniature integrated fluorescence microscope (i.e., miniscope) technology was used to visualize cocaine-induced changes in BBB permeability in awake, freely-moving rats., Methods: The miniscope was implanted in the prefrontal cortex of adult male rats. After recovery and acclimation, rats received an injection of cocaine (5-20 mg/kg ip) 15 minutes following iv infusion of sodium fluorescein, a low molecular weight tracer. Fluorescence intensity was recordedin vivo via the miniscope for 30 minutes or 24 hours post cocaine administration and served as an indicator of BBB permeability., Results: Results demonstrate that cocaine increased the sodium fluorescein extravasation in brain microcirculation in a dose-dependent manner 30 minutes, but not 24 hours after administration., Conclusion: We report for the first time using direct visualization of brain microcirculation with the miniscope technology in awake, freely-moving rats, that acute cocaine administration produced a transient increase in the BBB permeability., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
12. GPR55-mediated effects on brain microvascular endothelial cells and the blood-brain barrier.
- Author
-
Leo LM, Familusi B, Hoang M, Smith R, Lindenau K, Sporici KT, Brailoiu E, Abood ME, and Brailoiu GC
- Subjects
- Animals, Blood-Brain Barrier metabolism, Calcium metabolism, Cell Line, Dose-Response Relationship, Drug, Endothelial Cells metabolism, Male, Membrane Potentials drug effects, Microvessels drug effects, Microvessels metabolism, Rats, Rats, Sprague-Dawley, Blood-Brain Barrier drug effects, Calcium Signaling drug effects, Endothelial Cells drug effects, Lysophospholipids pharmacology, Receptors, Cannabinoid metabolism, Receptors, G-Protein-Coupled metabolism
- Abstract
GPR55, an atypical cannabinoid receptor activated by lysophosphatidylinositol (LPI) has been involved in various physiological and pathological processes. We examined the effect of GPR55 activation on rat brain microvascular endothelial cells (RBMVEC), an essential component of the blood-brain barrier (BBB). GPR55 was detected in RBMVEC by western blot and immunocytochemistry. Treatment of RBMVEC with LPI increased cytosolic Ca
2+ concentration, [Ca2+ ]i , in a concentration-dependent manner; the effect was abolished by the GPR55 antagonist, ML-193. Repetitive application of LPI induced tachyphylaxis. LPI-induced increase in [Ca2+ ]i was not sensitive to U-73122, a phospholipase C inhibitor, but was abolished by the blockade of voltage-gated Ca2+ channels or in Ca2+ -free saline, indicating that Ca2+ influx was involved in this response. LPI induced a biphasic change in RBMVEC membrane potential: a fast depolarization followed by a long-lasting hyperpolarization. The hyperpolarization phase was prevented by apamin and charibdotoxin, inhibitors of small- and intermediate-conductance Ca2+ -activated K+ channels (KCa ). Immunofluorescence studies indicate that LPI produced transient changes in tight and adherens junctions proteins and F-actin stress fibers. LPI decreased the electrical resistance of RBMVEC monolayer assessed with Electric Cell-Substrate Impedance Sensing (ECIS) in a dose-dependent manner. In vivo studies indicate that systemic administration of LPI increased the permeability of the BBB, assessed with Evans Blue method. Taken together, our results indicate that GPR55 activation modulates the function of endothelial cells of brain microvessels, produces a transient reduction in endothelial barrier function and increases BBB permeability., (Copyright © 2019 IBRO. Published by Elsevier Ltd. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
13. Choline Is an Intracellular Messenger Linking Extracellular Stimuli to IP 3 -Evoked Ca 2+ Signals through Sigma-1 Receptors.
- Author
-
Brailoiu E, Chakraborty S, Brailoiu GC, Zhao P, Barr JL, Ilies MA, Unterwald EM, Abood ME, and Taylor CW
- Subjects
- Animals, Cell Line, Humans, MCF-7 Cells, Mice, Phospholipase D metabolism, Sigma-1 Receptor, Calcium Signaling, Choline metabolism, Inositol 1,4,5-Trisphosphate Receptors metabolism, Receptors, sigma metabolism
- Abstract
Sigma-1 receptors (Sig-1Rs) are integral ER membrane proteins. They bind diverse ligands, including psychoactive drugs, and regulate many signaling proteins, including the inositol 1,4,5-trisphosphate receptors (IP
3 Rs) that release Ca2+ from the ER. The endogenous ligands of Sig-1Rs are unknown. Phospholipase D (PLD) cleaves phosphatidylcholine to choline and phosphatidic acid (PA), with PA assumed to mediate all downstream signaling. We show that choline is also an intracellular messenger. Choline binds to Sig-1Rs, it mimics other Sig-1R agonists by potentiating Ca2+ signals evoked by IP3 Rs, and it is deactivated by metabolism. Receptors, by stimulating PLC and PLD, deliver two signals to IP3 Rs: IP3 activates IP3 Rs, and choline potentiates their activity through Sig-1Rs. Choline is also produced at synapses by degradation of acetylcholine. Choline uptake by transporters activates Sig-1Rs and potentiates Ca2+ signals. We conclude that choline is an endogenous agonist of Sig-1Rs linking extracellular stimuli, and perhaps synaptic activity, to Ca2+ signals., (Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
14. Effects of Platelet-Activating Factor on Brain Microvascular Endothelial Cells.
- Author
-
Brailoiu E, Barlow CL, Ramirez SH, Abood ME, and Brailoiu GC
- Subjects
- Animals, Brain drug effects, Calcium metabolism, Calcium Channels, L-Type metabolism, Calcium Signaling drug effects, Calcium Signaling physiology, Capillary Permeability drug effects, Capillary Permeability physiology, Cations, Divalent metabolism, Cell Survival physiology, Cells, Cultured, Cytosol metabolism, Endothelial Cells drug effects, Membrane Potentials drug effects, Membrane Potentials physiology, Microvessels drug effects, Rats, Brain blood supply, Brain metabolism, Endothelial Cells metabolism, Microvessels metabolism, Platelet Activating Factor metabolism
- Abstract
Platelet-activating factor (PAF) is a potent phospholipid mediator that exerts various pathophysiological effects by interacting with a G protein-coupled receptor. PAF has been reported to increase the permeability of the blood-brain barrier (BBB) via incompletely characterized mechanisms. We investigated the effect of PAF on rat brain microvascular endothelial cells (RBMVEC), a critical component of the BBB. PAF produced a dose-dependent increase in cytosolic Ca
2+ concentration; the effect was prevented by the PAF receptor antagonist, WEB2086. The effect of PAF on cytosolic Ca2+ was abolished in Ca2+ -free saline or in the presence of L-type voltage-gated Ca2+ channel inhibitor, nifedipine, indicating that Ca2+ influx is critical for PAF-induced increase in cytosolic Ca2+ . PAF produced RBMVEC depolarization; the effect was inhibited by WEB2086. In cells loaded with [(4-amino-5-methylamino-2',7'-difluoro-fluorescein)diacetate] (DAF-FM), a nitric oxide (NO)-sensitive fluorescent dye, PAF increased the NO level; the effect was prevented by WEB2086, nifedipine or by l-NAME, an inhibitor of NO synthase. Immunocytochemistry studies indicate that PAF reduced the immunostaining of ZO-1, a tight junction-associated protein, increased F-actin fibers, and produced intercellular gaps. PAF produced a decrease in RBMVEC monolayer electrical resistance assessed with Electric Cell-Substrate Impedance Sensing (ECIS), indicative of a disruption of endothelial barrier function. In vivo studies indicate that PAF increased the BBB permeability, assessed with sodium fluorescein and Evans Blue methods, via PAF receptor-dependent mechanisms, consequent to Ca2+ influx and increased NO levels. Our studies reveal that PAF alters the BBB permeability by multiple mechanisms, which may be relevant for central nervous system (CNS) inflammatory disorders., (Copyright © 2018 IBRO. Published by Elsevier Ltd. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
15. Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor.
- Author
-
Bertini S, Chicca A, Gado F, Arena C, Nieri D, Digiacomo M, Saccomanni G, Zhao P, Abood ME, Macchia M, Gertsch J, and Manera C
- Subjects
- Allosteric Regulation drug effects, Dose-Response Relationship, Drug, HEK293 Cells, Humans, Molecular Structure, Phenylurea Compounds chemical synthesis, Phenylurea Compounds chemistry, Pyridines chemical synthesis, Pyridines chemistry, Structure-Activity Relationship, Phenylurea Compounds pharmacology, Pyridines pharmacology, Receptor, Cannabinoid, CB1 metabolism
- Abstract
In this work, we explored the molecular framework of the known CB1R allosteric modulator PSNCBAM-1 with the aim to generate new bioactive analogs and to deepen the structure-activity relationships of this type of compounds. In particular, the introduction of a NH group between the pyridine ring and the phenyl nucleus generated the amino-phenyl-urea derivative SN15b that behaved as a positive allosteric modulator (PAM), increasing the CB1R binding affinity of the orthosteric ligand CP55,940. The functional activity was evaluated using serum response element (SRE) assay, which assesses the CB1R-dependent activation of the MAPK/ERK signaling pathway. SN15b and the biphenyl-urea analog SC4a significantly inhibited the response produced by CP55,940 in the low µM range, thus behaving as negative allosteric modulators (NAMs). The new derivatives presented here provide further insights about the modulation of CB1R binding and functional activity by allosteric ligands., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
16. Modulation of cardiac vagal tone by bradykinin acting on nucleus ambiguus.
- Author
-
Brailoiu E, McGuire M, Shuler SA, Deliu E, Barr JL, Abood ME, and Brailoiu GC
- Subjects
- Animals, Animals, Newborn, Barbiturates metabolism, Bradykinin analogs & derivatives, Bradykinin Receptor Antagonists pharmacology, Calcium metabolism, Calcium Channel Blockers pharmacology, Cells, Cultured, Endoplasmic Reticulum drug effects, Endoplasmic Reticulum metabolism, Isoxazoles metabolism, Male, Medulla Oblongata drug effects, Membrane Potentials drug effects, Rats, Rats, Sprague-Dawley, Vagus Nerve drug effects, Bradykinin pharmacology, Heart Rate drug effects, Medulla Oblongata cytology, Neurons drug effects, Vagus Nerve physiology, Vasodilator Agents pharmacology
- Abstract
Bradykinin (BK), a component of the kallikrein-kininogen-kinin system exerts multiple effects via B1 and B2 receptor activation. In the cardiovascular system, bradykinin has cardioprotective and vasodilator properties. We investigated the effect of BK on cardiac-projecting neurons of nucleus ambiguus, a key site for the parasympathetic cardiac regulation. BK produced a dose-dependent increase in cytosolic Ca
2+ concentration. Pretreatment with HOE140, a B2 receptor antagonist, but not with R715, a B1 receptor antagonist, abolished the response to BK. A selective B2 receptor agonist, but not a B1 receptor agonist, elicited an increase in cytosolic Ca2+ similarly to BK. Inhibition of N-type voltage-gated Ca2+ channels with ω-conotoxin GVIA had no effect on the Ca2+ signal produced by BK, while pretreatment with ω-conotoxin MVIIC, a blocker of P/Q-type of Ca2+ channels, significantly diminished the effect of BK. Pretreatment with xestospongin C and 2-aminoethoxydiphenyl borate, antagonists of inositol 1,4,5-trisphosphate receptors, abolished the response to BK. Inhibition of ryanodine receptors reduced the BK-induced Ca2+ increase, while disruption of lysosomal Ca2+ stores with bafilomycin A1 did not affect the response. BK produced a dose-dependent depolarization of nucleus ambiguus neurons, which was prevented by the B2 receptor antagonist. In vivo studies indicate that microinjection of BK into nucleus ambiguus elicited bradycardia in conscious rats via B2 receptors. In summary, in cardiac vagal neurons of nucleus ambiguus, BK activates B2 receptors promoting Ca2+ influx and Ca2+ release from endoplasmic reticulum, and membrane depolarization; these effects are translated in vivo by bradycardia., (Copyright © 2017 IBRO. Published by Elsevier Ltd. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
17. Understanding the endocannabinoid system as a modulator of the trigeminal pain response to concussion.
- Author
-
Elliott MB, Ward SJ, Abood ME, Tuma RF, and Jallo JI
- Abstract
Post-traumatic headache is the most common symptom of postconcussion syndrome and becomes a chronic neurological disorder in a substantial proportion of patients. This review provides a brief overview of the epidemiology of postconcussion headache, research models used to study this disorder, as well as the proposed mechanisms. An objective of this review is to enhance the understanding of how the endogenous cannabinoid system is essential for maintaining the balance of the CNS and regulating inflammation after injury, and in turn making the endocannabinoid system a potential modulator of the trigeminal response to concussion. The review describes the role of endocannabinoid modulation of pain and the potential for use of phytocannabinoids to treat pain, migraine and concussion., Competing Interests: Financial & competing interests disclosure The authors thank the Department of Neurosurgery, the Jefferson Headache Center, and Vickie and Jack Farber Institute for their continued support. Related research support is provided from DoD W81XWH-14-1-0594 to MB Elliott and P30 DA013429 to ME Abood, SJ Ward and RF Tuma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
- Published
- 2017
- Full Text
- View/download PDF
18. N-arachidonoyl glycine, another endogenous agonist of GPR55.
- Author
-
Console-Bram L, Ciuciu SM, Zhao P, Zipkin RE, Brailoiu E, and Abood ME
- Subjects
- Animals, CHO Cells, Cricetulus, Dose-Response Relationship, Drug, Gene Expression Regulation, Glycine pharmacology, Humans, Inositol 1,4,5-Trisphosphate Receptors genetics, Inositol 1,4,5-Trisphosphate Receptors metabolism, Kinetics, Mitogen-Activated Protein Kinase 1 antagonists & inhibitors, Mitogen-Activated Protein Kinase 1 genetics, Mitogen-Activated Protein Kinase 1 metabolism, Mitogen-Activated Protein Kinase 3 antagonists & inhibitors, Mitogen-Activated Protein Kinase 3 genetics, Mitogen-Activated Protein Kinase 3 metabolism, Quinolines pharmacology, Receptors, Cannabinoid, Receptors, G-Protein-Coupled agonists, Receptors, G-Protein-Coupled metabolism, Arachidonic Acids pharmacology, Calcium metabolism, Glycine analogs & derivatives, Receptors, G-Protein-Coupled genetics
- Abstract
Interest in lipoamino acids as endogenous modulators of G-protein coupled receptors has escalated due to their involvement in a variety of physiologic processes. In particular, a role for these amino acid conjugates has emerged in the endocannabinoid system. The study presented herein investigated the effects of N-arachidonoyl glycine (NAGly) on a candidate endocannabinoid receptor, GPR55. Our novel findings reveal that NAGly induces concentration dependent increases in calcium mobilization and mitogen-activated protein kinase activities in HAGPR55/CHO cells. These increases were attenuated by the selective GPR55 antagonist ML193 (N-[4-[[(3,4-Dimethyl-5-isoxazolyl)amino]sulfonyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide), supporting receptor mediated signaling. To our knowledge this is the first report identifying GPR55 as a target of the endogenous lipoamino acid, NAGly., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
19. HIV Tat excites D1 receptor-like expressing neurons from rat nucleus accumbens.
- Author
-
Brailoiu GC, Deliu E, Barr JL, Console-Bram LM, Ciuciu AM, Abood ME, Unterwald EM, and Brailoiu E
- Subjects
- Animals, Calcium metabolism, Cells, Cultured, Cocaine pharmacology, Dose-Response Relationship, Drug, Drug Synergism, Female, Male, Neurons metabolism, Nucleus Accumbens drug effects, Rats, Signal Transduction physiology, Sodium metabolism, tat Gene Products, Human Immunodeficiency Virus pharmacology, Neurons physiology, Nucleus Accumbens physiology, Receptors, Dopamine D1 metabolism, tat Gene Products, Human Immunodeficiency Virus physiology
- Abstract
Background: HIV-1 infection and drug abuse are frequently co-morbid and their association greatly increases the severity of HIV-1-induced neuropathology. While nucleus accumbens (NAcc) function is severely perturbed by drugs of abuse, little is known about how HIV-1 infection affects NAcc., Methods: We used calcium and voltage imaging to investigate the effect of HIV-1 trans-activator of transcription (Tat) on rat NAcc. Based on previous neuronal studies, we hypothesized that Tat modulates intracellular Ca
2+ homeostasis of NAcc neurons., Results: We provide evidence that Tat triggers a Ca2+ signaling cascade in NAcc medium spiny neurons (MSN) expressing D1-like dopamine receptors leading to neuronal depolarization. Firstly, Tat induced inositol 1,4,5-trisphsophate (IP3 ) receptor-mediated Ca2+ release from endoplasmic reticulum, followed by Ca2+ and Na+ influx via transient receptor potential canonical channels. The influx of cations depolarizes the membrane promoting additional Ca2+ entry through voltage-gated P/Q-type Ca2+ channels and opening of tetrodotoxin-sensitive Na+ channels. By activating this mechanism, Tat elicits a feed-forward depolarization increasing the excitability of D1-phosphatidylinositol-linked NAcc MSN. We previously found that cocaine targets NAcc neurons directly (independent of the inhibition of dopamine transporter) only when IP3 -generating mechanisms are concomitantly initiated. When tested here, cocaine produced a dose-dependent potentiation of the effect of Tat on cytosolic Ca2+ ., Conclusion: We describe for the first time a HIV-1 Tat-triggered Ca2+ signaling in MSN of NAcc involving TRPC and depolarization and a potentiation of the effect of Tat by cocaine, which may be relevant for the reward axis in cocaine-abusing HIV-1-positive patients., (Copyright © 2017 Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
20. Design, synthesis and biological evaluation of GPR55 agonists.
- Author
-
Fakhouri L, Cook CD, Al-Huniti MH, Console-Bram LM, Hurst DP, Spano MBS, Nasrallah DJ, Caron MG, Barak LS, Reggio PH, Abood ME, and Croatt MP
- Subjects
- Dose-Response Relationship, Drug, Humans, Molecular Structure, Receptors, Cannabinoid, Structure-Activity Relationship, Thiourea analogs & derivatives, Thiourea chemical synthesis, Drug Design, Receptors, G-Protein-Coupled agonists, Thiourea pharmacology
- Abstract
GPR55, a G protein-coupled receptor, is an attractive target to alleviate inflammatory and neuropathic pain and treat osteoporosis and cancer. Identifying a potent and selective ligand will aid to further establish the specific physiological roles and pharmacology of the receptor. Towards this goal, a targeted library of 22 compounds was synthesized in a modular fashion to obtain structure-activity relationship information. The general route consisted of coupling a variety of p-aminophenyl sulfonamides to isothiocyanates to form acylthioureas. For the synthesis of a known naphthyl ethyl alcohol motif, route modification led to a shorter and more efficient process. The 22 analogues were analyzed for their ability to serve as agonists at GPR55 and valuable information for both ends of the molecule was ascertained., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
21. Mechanisms of modulation of brain microvascular endothelial cells function by thrombin.
- Author
-
Brailoiu E, Shipsky MM, Yan G, Abood ME, and Brailoiu GC
- Subjects
- Actins metabolism, Animals, Blood-Brain Barrier drug effects, Calcium metabolism, Calcium Signaling drug effects, Calcium Signaling physiology, Capillary Permeability drug effects, Capillary Permeability physiology, Cardiovascular Agents administration & dosage, Cardiovascular Agents metabolism, Cell Line, Endoplasmic Reticulum drug effects, Endoplasmic Reticulum metabolism, Endothelial Cells drug effects, Humans, Inositol 1,4,5-Trisphosphate Receptors metabolism, Microvessels drug effects, Mitochondria drug effects, Mitochondria metabolism, Nitric Oxide metabolism, Nitric Oxide Synthase antagonists & inhibitors, Nitric Oxide Synthase metabolism, Rats, Reactive Oxygen Species metabolism, Receptor, PAR-1 antagonists & inhibitors, Receptor, PAR-1 metabolism, Thrombin administration & dosage, Tight Junctions drug effects, Tight Junctions metabolism, Blood-Brain Barrier metabolism, Endothelial Cells metabolism, Microvessels metabolism, Thrombin metabolism
- Abstract
Brain microvascular endothelial cells are a critical component of the blood-brain barrier. They form a tight monolayer which is essential for maintaining the brain homeostasis. Blood-derived proteases such as thrombin may enter the brain during pathological conditions like trauma, stroke, and inflammation and further disrupts the permeability of the blood-brain barrier, via incompletely characterized mechanisms. We examined the underlying mechanisms evoked by thrombin in rat brain microvascular endothelial cells (RBMVEC). Our results indicate that thrombin, acting on protease-activated receptor 1 (PAR1) increases cytosolic Ca
2+ concentration in RBMVEC via Ca2+ release from endoplasmic reticulum through inositol 1,4,5-trisphosphate receptors and Ca2+ influx from extracellular space. Thrombin increases nitric oxide production; the effect is abolished by inhibition of the nitric oxide synthase or by antagonism of PAR1 receptors. In addition, thrombin increases mitochondrial and cytosolic reactive oxygen species production via PAR1-dependent mechanisms. Immunocytochemistry studies indicate that thrombin increases F-actin stress fibers, and disrupts the tight junctions. Thrombin increased the RBMVEC permeability assessed by a fluorescent flux assay. Taken together, our results indicate multiple mechanisms by which thrombin modulates the function of RBMVEC and may contribute to the blood-brain barrier dysfunction., (Copyright © 2016 Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
22. Effects of VPAC1 activation in nucleus ambiguus neurons.
- Author
-
Gherghina FL, Tica AA, Deliu E, Abood ME, Brailoiu GC, and Brailoiu E
- Subjects
- Animals, Blood Pressure drug effects, Blood Pressure physiology, Bradycardia chemically induced, Bradycardia metabolism, Calcium metabolism, Calcium Signaling drug effects, Calcium Signaling physiology, Cells, Cultured, Endoplasmic Reticulum drug effects, Endoplasmic Reticulum metabolism, Female, Heart Rate drug effects, Heart Rate physiology, Male, Medulla Oblongata cytology, Medulla Oblongata drug effects, Membrane Potentials drug effects, Membrane Potentials physiology, Neuroanatomical Tract-Tracing Techniques, Neurons cytology, Neurons drug effects, Parasympatholytics pharmacology, Rats, Sprague-Dawley, Receptors, Vasoactive Intestinal Polypeptide, Type I agonists, Vagus Nerve cytology, Vagus Nerve drug effects, Vagus Nerve metabolism, Medulla Oblongata metabolism, Neurons metabolism, Receptors, Vasoactive Intestinal Polypeptide, Type I metabolism
- Abstract
The pituitary adenylyl cyclase-activating polypeptide (PACAP) and its G protein-coupled receptors, PAC1, VPAC1 and VPAC2 form a system involved in a variety of biological processes. Although some sympathetic stimulatory effects of this system have been reported, its central cardiovascular regulatory properties are poorly characterized. VPAC1 receptors are expressed in the nucleus ambiguus (nAmb), a key center controlling cardiac parasympathetic tone. In this study, we report that selective VPAC1 activation in rhodamine-labeled cardiac vagal preganglionic neurons of the rat nAmb produces inositol 1,4,5-trisphosphate receptor-mediated Ca
2+ mobilization, membrane depolarization and activation of P/Q-type Ca2+ channels. In vivo, this pathway converges onto transient reduction in heart rate of conscious rats. Therefore we demonstrate a VPAC1-dependent mechanism in the central parasympathetic regulation of the heart rate, adding to the complexity of PACAP-mediated cardiovascular modulation., Competing Interests: statement All authors declare that there are no conflicts of interest., (Copyright © 2017 Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
23. Structure-activity relationships of benzothiazole GPR35 antagonists.
- Author
-
Abdalhameed MM, Zhao P, Hurst DP, Reggio PH, Abood ME, and Croatt MP
- Subjects
- Benzothiazoles chemical synthesis, Benzothiazoles metabolism, Cell Line, Tumor, Humans, Inhibitory Concentration 50, Protein Binding, Receptors, G-Protein-Coupled genetics, Receptors, G-Protein-Coupled metabolism, Structure-Activity Relationship, Benzothiazoles chemistry, Receptors, G-Protein-Coupled antagonists & inhibitors
- Abstract
The first structure-activity relationships for a benzothiazole scaffold acting as an antagonist at GPR35 is presented. Analogues were designed based on a lead compound that was previously determined to have selective activity as a GPR35 antagonist. The synthetic route was modular in nature to independently explore the role of the middle and both ends of the scaffold. The activities of the analogues illustrate the importance of all three segments of the compound., (Copyright © 2016. Published by Elsevier Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
24. Identification of Crucial Amino Acid Residues Involved in Agonist Signaling at the GPR55 Receptor.
- Author
-
Lingerfelt MA, Zhao P, Sharir HP, Hurst DP, Reggio PH, and Abood ME
- Subjects
- Amino Acid Motifs, Binding Sites, Crystallography, X-Ray, Gene Expression, HEK293 Cells, Humans, Kinetics, Ligands, Lysophospholipids pharmacology, Molecular Docking Simulation, Mutation, Piperazines pharmacology, Protein Binding, Pyrrolidines pharmacology, Receptors, Cannabinoid, Receptors, G-Protein-Coupled agonists, Receptors, G-Protein-Coupled genetics, Receptors, G-Protein-Coupled metabolism, Receptors, Opioid, delta chemistry, Receptors, Opioid, delta genetics, Receptors, Opioid, delta metabolism, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins metabolism, Serum Response Factor chemistry, Serum Response Factor genetics, Serum Response Factor metabolism, Signal Transduction, Glycine max, Structural Homology, Protein, Thermodynamics, Lysophospholipids chemistry, Piperazines chemistry, Pyrrolidines chemistry, Receptors, G-Protein-Coupled chemistry, Recombinant Fusion Proteins chemistry, Serum Response Element
- Abstract
GPR55 is a newly deorphanized class A G-protein-coupled receptor that has been implicated in inflammatory pain, neuropathic pain, metabolic disorder, bone development, and cancer. Few potent GPR55 ligands have been identified to date. This is largely due to an absence of information about salient features of GPR55, such as residues important for signaling and residues implicated in the GPR55 signaling cascade. The goal of this work was to identify residues that are key for the signaling of the GPR55 endogenous ligand, l-α-lysophosphatidylinositol (LPI), as well as the signaling of the GPR55 agonist, ML184 {CID 2440433, 3-[4-(2,3-dimethylphenyl)piperazine-1-carbonyl]-N,N-dimethyl-4-pyrrolidin-1-ylbenzenesulfonamide}. Serum response element (SRE) and serum response factor (SRF) luciferase assays were used as readouts for studying LPI and ML184 signaling at the GPR55 mutants. A GPR55 R* model based on the recent δ-opioid receptor (DOR) crystal structure was used to interpret the resultant mutation data. Two residues were found to be crucial for agonist signaling at GPR55, K2.60 and E3.29, suggesting that these residues form the primary interaction site for ML184 and LPI at GPR55. Y3.32F, H(170)F, and F6.55A/L mutation results suggested that these residues are part of the orthosteric binding site for ML184, while Y3.32F and H(170)F mutation results suggest that these two residues are part of the LPI binding pocket. Y3.32L, M3.36A, and F6.48A mutation results suggest the importance of a Y3.32/M3.36/F6.48 cluster in the GPR55 signaling cascade. C(10)A and C(260)A mutations suggest that these residues form a second disulfide bridge in the extracellular domain of GPR55, occluding ligand extracellular entry in the TMH1-TMH7 region of GPR55. Taken together, these results provide the first set of discrete information about GPR55 residues important for LPI and ML184 signaling and for GPR55 activation. This information should aid in the rational design of next-generation GPR55 ligands and the creation of the first high-affinity GPR55 radioligand, a tool that is sorely needed in the field.
- Published
- 2017
- Full Text
- View/download PDF
25. CB 1 and CB 2 Receptor Pharmacology.
- Author
-
Howlett AC and Abood ME
- Subjects
- Alternative Splicing genetics, Animals, Humans, Phylogeny, Polymorphism, Genetic, Receptor, Cannabinoid, CB1 agonists, Receptor, Cannabinoid, CB1 genetics, Receptor, Cannabinoid, CB2 agonists, Receptor, Cannabinoid, CB2 genetics, Signal Transduction drug effects, Receptor, Cannabinoid, CB1 metabolism, Receptor, Cannabinoid, CB2 metabolism
- Abstract
The CB
1 and CB2 cannabinoid receptors (CB1 R, CB2 R) are members of the G protein-coupled receptor (GPCR) family that were identified over 20 years ago. CB1 Rs and CB2 Rs mediate the effects of Δ9 -tetrahydrocannabinol (Δ9 -THC), the principal psychoactive constituent of marijuana, and subsequently identified endogenous cannabinoids (endocannabinoids) anandamide and 2-arachidonoyl glycerol. CB1 Rs and CB2 Rs have both similarities and differences in their pharmacology. Both receptors recognize multiple classes of agonist and antagonist compounds and produce an array of distinct downstream effects. Natural polymorphisms and alternative splice variants may also contribute to their pharmacological diversity. As our knowledge of the distinct differences grows, we may be able to target select receptor conformations and their corresponding pharmacological responses. This chapter will discuss their pharmacological characterization, distribution, phylogeny, and signaling pathways. In addition, the effects of extended agonist exposure and how that affects signaling and expression patterns of the receptors are considered., (© 2017 Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
26. Protocols and Good Operating Practices in the Study of Cannabinoid Receptors.
- Author
-
Console-Bram LM, Zhao P, and Abood ME
- Subjects
- Guanosine 5'-O-(3-Thiotriphosphate) chemistry, HEK293 Cells, Humans, Protein Binding, Receptors, Cannabinoid chemistry, Receptors, Cannabinoid isolation & purification, Reproducibility of Results, Scintillation Counting, Signal Transduction, Sulfur Radioisotopes chemistry, Receptors, Cannabinoid physiology
- Abstract
With the approach of the 30th year since the pioneering discovery of a cannabinoid receptor in rat brain (Devane et al., 1988), the field of cannabinoid pharmacology and physiology has impacted human physiology at multiple levels. The development of highly specific and potent orthosteric ligands, as well as the blossoming field of allosteric ligand development, has placed the endocannabinoid system in the forefront as a modulator of a multitude of physiologic processes. Reproducibility among laboratories is especially important due to the development of novel tools to investigate the role(s) of the endocannabinoid system in human physiology, and to clarify the roles for medicinal marijuana. Any definitive role in normal, or diseased states, must be satisfied through the demonstration of a specific receptor-mediated event. This chapter provides working protocols for the study of cannabinoid receptor-ligand binding, as well as immediate and downstream G protein-dependent signaling assays to assess receptor function., (© 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
27. CB 1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling.
- Author
-
Gamage TF, Anderson JC, and Abood ME
- Abstract
Allosteric modulation of cannabinoid type-1 receptors (CB
1 ) is a novel means through which signaling bias may be exerted. Org27569 remains the most-characterized CB1 allosteric modulator yet there are conflicting reports regarding its effects on extracellular signal-regulated kinase (ERK) signaling. We conducted a systematic evaluation of Org27569 signaling through ERK. We have found that Org27569 is an antagonist of human CB1 (hCB1 ) mediated ERK signaling in HEK293 cells where it fully blocks CP55,940- but does not completely inhibit THC- and 2-AG-stimulated ERK1/2 activation. In hCB1 HEK293 cells, CP55,940 (1 μM) treatment produced a significant increase in puncta at 20, 40, 60, and 120 min, consistent with receptor internalization. Org27569 (10 μM) co-treatment prevented internalization at each time point and alone had no effect. These data demonstrate that Org27569 can block the CP55,940- induced internalization of CB1 receptors. Org27569 reduced basal ERK phosphorylation in hCB1 HEK293 cells but not in untransfected cells, demonstrating that Org27569 acts via the CB1 receptor to produce this effect. Furthermore, inverse agonism was through inhibition of Gi/o as overnight treatment with pertussis toxin abated this response. Finally, to delineate Org27569's effects on ERK1/2 in subcellular compartments, subcellular fractionation was performed; Org27569 produced a significant decrease in ERK phosphorylation in the nuclear-enriched and cytosolic fractions. Altogether, these data are consistent with previous studies demonstrating that CB1 -mediated ERK1/2 activation is Gi/o -dependent and that Org27569 is an inverse agonist of CB1 receptors. To our knowledge this is the first reported demonstration of inverse agonism of ERK signaling by Org27569., Competing Interests: Conflict of Interest: Authors have no conflict of interest concerning this study and have nothing to declare.- Published
- 2016
- Full Text
- View/download PDF
28. Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones.
- Author
-
Meza-Aviña ME, Lingerfelt MA, Console-Bram LM, Gamage TF, Sharir H, Gettys KE, Hurst DP, Kotsikorou E, Shore DM, Caron MG, Rao N, Barak LS, Abood ME, Reggio PH, and Croatt MP
- Subjects
- Animals, Arrestins metabolism, CHO Cells, Cricetulus, Humans, Molecular Docking Simulation, Oxadiazoles chemical synthesis, Piperidines chemical synthesis, Receptors, Cannabinoid, Receptors, G-Protein-Coupled metabolism, Structure-Activity Relationship, beta-Arrestins, Drug Design, Oxadiazoles chemistry, Oxadiazoles pharmacology, Piperidines chemistry, Piperidines pharmacology, Receptors, G-Protein-Coupled antagonists & inhibitors
- Abstract
A series of 1,3,4-oxadiazol-2-ones was synthesized and tested for activity as antagonists at GPR55 in cellular beta-arrestin redistribution assays. The synthesis was designed to be modular in nature so that a sufficient number of analogues could be rapidly accessed to explore initial structure-activity relationships. The design of analogues was guided by the docking of potential compounds into a model of the inactive form of GPR55. The results of the assays were used to learn more about the binding pocket of GPR55. With this oxadiazolone scaffold, it was determined that modification of the aryl group adjacent to the oxadiazolone ring was often detrimental and that the distal cyclopropane was beneficial for activity. These results will guide further exploration of this receptor., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
29. Allosteric Modulators: A Side Door.
- Author
-
Abood ME
- Subjects
- Humans, Molecular Conformation, Receptor, Cannabinoid, CB1 chemistry, Receptor, Cannabinoid, CB1 drug effects, Structure-Activity Relationship, Allosteric Regulation drug effects, Allosteric Site drug effects
- Abstract
Allosteric modulators of the cannabinoid CB1 receptor were first discovered in 2005. Since then, although both negative and positive allosteric modulators have been uncovered, many questions remain about their site(s) of action, as well as the basis of their signaling. The described covalent probe with improved potency and efficacy will facilitate these studies.
- Published
- 2016
- Full Text
- View/download PDF
30. Cocaine inhibits store-operated Ca2+ entry in brain microvascular endothelial cells: critical role for sigma-1 receptors.
- Author
-
Brailoiu GC, Deliu E, Console-Bram LM, Soboloff J, Abood ME, Unterwald EM, and Brailoiu E
- Subjects
- Animals, Calcium Channels metabolism, Calcium Signaling drug effects, Calcium Signaling physiology, Cells, Cultured, Endothelial Cells drug effects, Microvessels drug effects, Rats, Receptors, sigma agonists, Sigma-1 Receptor, Calcium metabolism, Cocaine pharmacology, Endothelial Cells metabolism, Microvessels metabolism, Receptors, sigma physiology
- Abstract
Sigma-1 receptor (Sig-1R) is an intracellular chaperone protein with many ligands, located at the endoplasmic reticulum (ER). Binding of cocaine to Sig-1R has previously been found to modulate endothelial functions. In the present study, we show that cocaine dramatically inhibits store-operated Ca(2+) entry (SOCE), a Ca(2+) influx mechanism promoted by depletion of intracellular Ca(2+) stores, in rat brain microvascular endothelial cells (RBMVEC). Using either Sig-1R shRNA or pharmacological inhibition with the unrelated Sig-1R antagonists BD-1063 and NE-100, we show that cocaine-induced SOCE inhibition is dependent on Sig-1R. In addition to revealing new insight into fundamental mechanisms of cocaine-induced changes in endothelial function, these studies indicate an unprecedented role for Sig-1R as a SOCE inhibitor., (© 2016 Authors; published by Portland Press Limited.)
- Published
- 2016
- Full Text
- View/download PDF
31. Mechanisms of activation of nucleus accumbens neurons by cocaine via sigma-1 receptor-inositol 1,4,5-trisphosphate-transient receptor potential canonical channel pathways.
- Author
-
Barr JL, Deliu E, Brailoiu GC, Zhao P, Yan G, Abood ME, Unterwald EM, and Brailoiu E
- Subjects
- Adenosine Triphosphate pharmacology, Animals, Behavior, Animal drug effects, Calcium metabolism, Calcium Signaling drug effects, Cells, Cultured, Endoplasmic Reticulum metabolism, Imidazoles pharmacology, Inositol 1,4,5-Trisphosphate pharmacology, Locomotion drug effects, Male, Membrane Potentials drug effects, Neurons cytology, Neurons metabolism, Rats, Rats, Sprague-Dawley, TRPC Cation Channels metabolism, Sigma-1 Receptor, Cocaine pharmacology, Inositol 1,4,5-Trisphosphate Receptors metabolism, Neurons drug effects, Nucleus Accumbens cytology, Receptors, sigma metabolism
- Abstract
Cocaine promotes addictive behavior primarily by blocking the dopamine transporter, thus increasing dopamine transmission in the nucleus accumbens (nAcc); however, additional mechanisms are continually emerging. Sigma-1 receptors (σ1Rs) are known targets for cocaine, yet the mechanisms underlying σ1R-mediated effects of cocaine are incompletely understood. The present study examined direct effects of cocaine on dissociated nAcc neurons expressing phosphatidylinositol-linked D1 receptors. Endoplasmic reticulum-located σ1Rs and inositol 1,4,5-trisphosphate (IP3) receptors (IP3Rs) were targeted using intracellular microinjection. IP3 microinjection robustly elevated intracellular Ca(2+) concentration, [Ca(2+)]i. While cocaine alone was devoid of an effect, the IP3-induced response was σ1R-dependently enhanced by cocaine co-injection. Likewise, cocaine augmented the [Ca(2+)]i increase elicited by extracellularly applying an IP3-generating molecule (ATP), via σ1Rs. The cocaine-induced enhancement of the IP3/ATP-mediated Ca(2+) elevation occurred at pharmacologically relevant concentrations and was mediated by transient receptor potential canonical channels (TRPC). IP3 microinjection elicited a slight, transient depolarization, further converted to a greatly enhanced, prolonged response, by cocaine co-injection. The cocaine-triggered augmentation was σ1R-dependent, TRPC-mediated and contingent on [Ca(2+)]i elevation. ATP-induced depolarization was similarly enhanced by cocaine. Thus, we identify a novel mechanism by which cocaine promotes activation of D1-expressing nAcc neurons: enhancement of IP3R-mediated responses via σ1R activation at the endoplasmic reticulum, resulting in augmented Ca(2+) release and amplified depolarization due to subsequent stimulation of TRPC. In vivo, intra-accumbal blockade of σ1R or TRPC significantly diminished cocaine-induced hyperlocomotion and locomotor sensitization, endorsing a physio-pathological significance of the pathway identified in vitro., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
32. The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray.
- Author
-
Deliu E, Sperow M, Console-Bram L, Carter RL, Tilley DG, Kalamarides DJ, Kirby LG, Brailoiu GC, Brailoiu E, Benamar K, and Abood ME
- Subjects
- Animals, Animals, Newborn, Cells, Cultured, Female, Male, Membrane Potentials drug effects, Neurons physiology, Rats, Rats, Sprague-Dawley, Calcium metabolism, Lysophospholipids pharmacology, Pain Perception, Periaqueductal Gray physiology, Receptors, Cannabinoid genetics, Receptors, Cannabinoid metabolism
- Abstract
Emerging evidence indicates the involvement of GPR55 and its proposed endogenous ligand, lysophosphatidylinositol (LPI), in nociception, yet their role in central pain processing has not been explored. Using Ca(2+) imaging, we show here that LPI elicits concentration-dependent and GPR55-mediated increases in intracellular Ca(2+) levels in dissociated rat periaqueductal gray (PAG) neurons, which express GPR55 mRNA. This effect is mediated by Ca(2+) release from the endoplasmic reticulum via inositol 1,4,5-trisphosphate receptors and by Ca(2+) entry via P/Q-type of voltage-gated Ca(2+) channels. Moreover, LPI depolarizes PAG neurons and upon intra-PAG microinjection, reduces nociceptive threshold in the hot-plate test. Both these effects are dependent on GPR55 activation, because they are abolished by pretreatment with ML-193 [N-(4-(N-(3,4-dimethylisoxazol-5-yl)sulfamoyl)-phenyl)-6,8-dimethyl-2-(pyridin-2-yl)quinoline-4-carboxamide], a selective GPR55 antagonist. Thus, we provide the first pharmacological evidence that GPR55 activation at central levels is pronociceptive, suggesting that interfering with GPR55 signaling in the PAG may promote analgesia., (Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2015
- Full Text
- View/download PDF
33. G protein-coupled estrogen receptor-mediated effects on cytosolic calcium and nanomechanics in brain microvascular endothelial cells.
- Author
-
Altmann JB, Yan G, Meeks JF, Abood ME, Brailoiu E, and Brailoiu GC
- Subjects
- Animals, Biomechanical Phenomena, Blood-Brain Barrier cytology, Blood-Brain Barrier physiology, Capillaries cytology, Cells, Cultured, Cerebrovascular Circulation, Membrane Potentials physiology, Microscopy, Atomic Force, Nitric Oxide metabolism, Rats, Receptors, G-Protein-Coupled agonists, Calcium physiology, Capillaries metabolism, Cytosol physiology, Endothelial Cells metabolism, Receptors, Estrogen physiology, Receptors, G-Protein-Coupled physiology
- Abstract
G protein-coupled estrogen receptor (GPER) is a relatively recently identified non-nuclear estrogen receptor, expressed in several tissues, including brain and blood vessels. The mechanisms elicited by GPER activation in brain microvascular endothelial cells are incompletely understood. The purpose of this work was to assess the effects of GPER activation on cytosolic Ca(2+) concentration, [Ca(2+)](i), nitric oxide production, membrane potential and cell nanomechanics in rat brain microvascular endothelial cells (RBMVEC). Extracellular but not intracellular administration of G-1, a selective GPER agonist, or extracellular administration of 17-β-estradiol and tamoxifen, increased [Ca(2+)](i) in RBMVEC. The effect of G-1 on [Ca(2+)](i) was abolished in Ca(2+) -free saline or in the presence of a L-type Ca(2+) channel blocker. G-1 increased nitric oxide production in RBMVEC; the effect was prevented by NG-nitro-l-arginine methyl ester. G-1 elicited membrane hyperpolarization that was abolished by the antagonists of small and intermediate-conductance Ca(2+) -activated K(+) channels, apamin, and charibdotoxin. GPER-mediated responses were sensitive to G-36, a GPER antagonist. In addition, atomic force microscopy studies revealed that G-1 increased the modulus of elasticity, indicative of cytoskeletal changes and increase in RBMVEC stiffness. Our results unravel the mechanisms underlying GPER-mediated effects in RBMVEC with implications for the effect of estrogen on cerebral microvasculature. Activation of the G protein-coupled estrogen receptor (GPER) in rat brain microvascular endothelial cells (RBMVEC) increases [Ca(2+)](i) by promoting Ca(2+) influx. The increase in [Ca(2+)](i) leads to membrane hyperpolarization, nitric oxide (NO) production, and to cytoskeletal changes and increased cell stiffness. Our results unravel the mechanisms underlying GPER-mediated effects in RBMVEC with implications for the effect of estrogen on cerebral microvasculature., (© 2015 International Society for Neurochemistry.)
- Published
- 2015
- Full Text
- View/download PDF
34. HIV-gp120 and physical dependence to buprenorphine.
- Author
-
Palma J, Abood ME, and Benamar K
- Subjects
- Animals, Buprenorphine therapeutic use, HIV Infections complications, Male, Methadone therapeutic use, Pain complications, Pain drug therapy, Rats, Rats, Sprague-Dawley, Buprenorphine adverse effects, HIV Envelope Protein gp120 pharmacology, Methadone adverse effects, Opioid-Related Disorders complications, Periaqueductal Gray drug effects
- Abstract
Background: Opioids are among the most effective and commonly used analgesics in clinical practice for severe pain. However, the use of opioid medications is clinically limited by several adverse properties including dependence. While opioid dependence is a complex health condition, the treatment of HIV-infected individuals with opioid dependence presents additional challenges. The goal of this study was to examine the physical dependence to buprenorphine in the context of HIV., Methods: Young adult male rats (Sprague-Dawley) were pretreated with HIV-1 envelope glycoprotein 120 (gp120) injected into the periaqueductal gray area (PAG) and we examined the impact on physical dependence to opioid., Results: It was found that the physical dependence to methadone occurred earlier than that to buprenorphine, and that gp120 did not enhance or precipitate the buprenorphine withdrawal., Conclusion: The results suggest that buprenorphine could be the better therapeutic option to manage opioid dependence in HIV., (Copyright © 2015. Published by Elsevier Ireland Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
35. Absence of ALOX5 gene prevents stress-induced memory deficits, synaptic dysfunction and tauopathy in a mouse model of Alzheimer's disease.
- Author
-
Joshi YB, Giannopoulos PF, Chu J, Sperow M, Kirby LG, Abood ME, and Praticò D
- Subjects
- Alzheimer Disease complications, Alzheimer Disease pathology, Alzheimer Disease psychology, Animals, Arachidonate 5-Lipoxygenase deficiency, Disease Models, Animal, Female, Gene Expression Regulation, Glycogen Synthase Kinase 3 genetics, Glycogen Synthase Kinase 3 metabolism, Glycogen Synthase Kinase 3 beta, Humans, Immobilization psychology, Long-Term Potentiation genetics, Male, Mental Recall, Mice, Mice, Transgenic, Phosphorylation, Social Isolation psychology, Stress, Psychological complications, Stress, Psychological pathology, Stress, Psychological psychology, Synaptic Transmission, tau Proteins chemistry, tau Proteins metabolism, Alzheimer Disease genetics, Arachidonate 5-Lipoxygenase genetics, Stress, Psychological genetics, tau Proteins genetics
- Abstract
Although the initial events of Alzheimer's disease (AD) are still not known, it is clear that the disease in its sporadic form results from the combination of genetic and environmental risk factors. Among the latter, behavioral stress has been increasingly recognized as an important factor in the propagation of AD. However, the mechanisms underlying this modulation remain to be fully investigated. Since stress up-regulates the ALOX5 gene product, 5-lipoxygenase (5LO), herein we investigated its role in modulating stress-dependent development of the AD phenotype. To reach this goal, triple transgenic (3xTg) mice and 3xTg genetically deficient for 5LO were investigated after undergoing a restraint/isolation paradigm. In the present paper, we found that 28 days of restraint/isolation stress worsened tau phosphorylation and solubility, increased glycogen synthase kinase 3β activity, compromised long-term potentiation and impaired fear-conditioned memory recall in 3xTg animals, but not in 3xTg animals lacking 5LO (3xTg/5LO-/-). These results highlight the novel functional role that the ALOX5 gene plays in the development of the biochemical, electrophysiological and behavioral sequelae of stress in the AD context. They provide critical support that this gene and its expressed protein are viable therapeutic targets to prevent the onset or delay the progression of AD in individuals exposed to this risk factor., (© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2014
- Full Text
- View/download PDF
36. Two-pore channels provide insight into the evolution of voltage-gated Ca2+ and Na+ channels.
- Author
-
Rahman T, Cai X, Brailoiu GC, Abood ME, Brailoiu E, and Patel S
- Subjects
- Animals, Asparagine metabolism, Base Sequence, Cations metabolism, Likelihood Functions, Models, Genetic, Molecular Docking Simulation, Molecular Sequence Data, NADP analogs & derivatives, NADP metabolism, Sea Urchins, Sequence Analysis, DNA, Sequence Homology, Calcium Channels genetics, Calcium Channels, N-Type genetics, Evolution, Molecular, Gene Duplication genetics, Phylogeny, Voltage-Gated Sodium Channels genetics
- Abstract
Four-domain voltage-gated Ca(2+) and Na(+) channels (CaV, NaV) underpin nervous system function and likely emerged upon intragenic duplication of a primordial two-domain precursor. To investigate if two-pore channels (TPCs) may represent an intermediate in this evolutionary transition, we performed molecular docking simulations with a homology model of TPC1, which suggested that the pore region could bind antagonists of CaV or NaV. CaV or NaV antagonists blocked NAADP (nicotinic acid adenine dinucleotide phosphate)-evoked Ca(2+) signals in sea urchin egg preparations and in intact cells that overexpressed TPC1. By sequence analysis and inspection of the model, we predicted a noncanonical selectivity filter in animal TPCs in which the carbonyl groups of conserved asparagine residues are positioned to coordinate cations. In contrast, a distinct clade of TPCs [TPCR (for TPC-related)] in several unicellular species had ion selectivity filters with acidic residues more akin to CaV. TPCRs were predicted to interact strongly with CaV antagonists. Our data suggest that acquisition of a "blueprint" pharmacological profile and changes in ion selectivity within four-domain voltage-gated ion channels may have predated intragenic duplication of an ancient two-domain ancestor., (Copyright © 2014, American Association for the Advancement of Science.)
- Published
- 2014
- Full Text
- View/download PDF
37. CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides.
- Author
-
Lucchesi V, Hurst DP, Shore DM, Bertini S, Ehrmann BM, Allarà M, Lawrence L, Ligresti A, Minutolo F, Saccomanni G, Sharir H, Macchia M, Di Marzo V, Abood ME, Reggio PH, and Manera C
- Subjects
- Cell Line, Tumor, Humans, Ligands, Models, Molecular, Molecular Docking Simulation, Naphthyridines chemistry, Receptor, Cannabinoid, CB1 agonists, Receptor, Cannabinoid, CB2 chemistry, Structure-Activity Relationship, Naphthyridines chemical synthesis, Receptor, Cannabinoid, CB2 agonists, Receptor, Cannabinoid, CB2 antagonists & inhibitors
- Abstract
We have recently identified 1,8-naphthyridin-2(1H)-one-3-carboxamide as a new scaffold very suitable for the development of new CB2 receptor potent and selective ligands. In this paper we describe a number of additional derivatives in which the same central scaffold has been variously functionalized in position 1 or 6. All new compounds showed high selectivity and affinity in the nanomolar range for the CB2 receptor. Furthermore, we found that their functional activity is controlled by the presence of the substituents at position C-6 of the naphthyridine scaffold. In fact, the introduction of substituents in this position determined a functionality switch from agonist to antagonists/inverse agonists. Finally, docking studies showed that the difference between the pharmacology of these ligands may be in the ability/inability to block the Toggle Switch W6.48(258) (χ1 g+ → trans) transition.
- Published
- 2014
- Full Text
- View/download PDF
38. The Two-pore channel (TPC) interactome unmasks isoform-specific roles for TPCs in endolysosomal morphology and cell pigmentation.
- Author
-
Lin-Moshier Y, Keebler MV, Hooper R, Boulware MJ, Liu X, Churamani D, Abood ME, Walseth TF, Brailoiu E, Patel S, and Marchant JS
- Subjects
- Animals, Calcium Signaling, Cell Proliferation, Chromatography, Affinity, HEK293 Cells, Humans, NADP analogs & derivatives, NADP metabolism, Protein Binding, Protein Isoforms metabolism, Reproducibility of Results, Xenopus, rab GTP-Binding Proteins metabolism, Calcium Channels metabolism, Endosomes metabolism, Lysosomes metabolism, Pigmentation
- Abstract
The two-pore channels (TPC1 and TPC2) belong to an ancient family of intracellular ion channels expressed in the endolysosomal system. Little is known about how regulatory inputs converge to modulate TPC activity, and proposed activation mechanisms are controversial. Here, we compiled a proteomic characterization of the human TPC interactome, which revealed that TPCs complex with many proteins involved in Ca(2+) homeostasis, trafficking, and membrane organization. Among these interactors, TPCs were resolved to scaffold Rab GTPases and regulate endomembrane dynamics in an isoform-specific manner. TPC2, but not TPC1, caused a proliferation of endolysosomal structures, dysregulating intracellular trafficking, and cellular pigmentation. These outcomes required both TPC2 and Rab activity, as well as their interactivity, because TPC2 mutants that were inactive, or rerouted away from their endogenous expression locale, or deficient in Rab binding, failed to replicate these outcomes. Nicotinic acid adenine dinucleotide phosphate (NAADP)-evoked Ca(2+) release was also impaired using either a Rab binding-defective TPC2 mutant or a Rab inhibitor. These data suggest a fundamental role for the ancient TPC complex in trafficking that holds relevance for lysosomal proliferative scenarios observed in disease.
- Published
- 2014
- Full Text
- View/download PDF
39. Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors.
- Author
-
Brailoiu GC, Deliu E, Marcu J, Hoffman NE, Console-Bram L, Zhao P, Madesh M, Abood ME, and Brailoiu E
- Subjects
- Benzoxazines metabolism, Benzoxazines pharmacology, Calcium Signaling drug effects, Cell Line, Humans, Intracellular Membranes metabolism, Molecular Sequence Data, Morpholines metabolism, Morpholines pharmacology, Naphthalenes metabolism, Naphthalenes pharmacology, Receptor, Cannabinoid, CB2 agonists, Receptor, Cannabinoid, CB2 metabolism, Calcium Signaling physiology, Intracellular Membranes chemistry, Receptor, Cannabinoid, CB2 chemistry
- Abstract
The therapeutic and psychoactive properties of cannabinoids have long been recognized. The type 2 receptor for cannabinoids (CB2) has emerged as an important therapeutic target in several pathologies, as it mediates beneficial effects of cannabinoids while having little if any psychotropic activity. Difficulties associated with the development of CB2-based therapeutic agents have been related to its intricate pharmacology, including the species specificity and functional selectivity of the CB2-initiated responses. We postulated that a plasmalemmal or subcellular location of the receptor may contribute to the differential signaling pathways initiated by its activation. To differentiate between these two, we used extracellular and intracellular administration of CB2 ligands and concurrent calcium imaging in CB2-expressing U2OS cells. We found that extracellular administration of anandamide was ineffective, whereas 2-arachidonoyl glycerol (2-AG) and WIN55,212-2 triggered delayed, CB2-dependent Ca(2+) responses that were Gq protein-mediated. When microinjected, all agonists elicited fast, transient, and dose-dependent elevations in intracellular Ca(2+) concentration upon activation of Gq-coupled CB2 receptors. The CB2 dependency was confirmed by the sensitivity to AM630, a selective CB2 antagonist, and by the unresponsiveness of untransfected U2OS cells to 2-AG, anandamide, or WIN55,212-2. Moreover, we provide functional and morphological evidence that CB2 receptors are localized at the endolysosomes, while their activation releases Ca(2+) from inositol 1,4,5-trisphosphate-sensitive- and acidic-like Ca(2+) stores. Our results support the functionality of intracellular CB2 receptors and their ability to couple to Gq and elicit Ca(2+) signaling. These findings add further complexity to CB2 receptor pharmacology and argue for careful consideration of receptor localization in the development of CB2-based therapeutic agents.
- Published
- 2014
- Full Text
- View/download PDF
40. Activation of GPR18 by cannabinoid compounds: a tale of biased agonism.
- Author
-
Console-Bram L, Brailoiu E, Brailoiu GC, Sharir H, and Abood ME
- Subjects
- Animals, Arachidonic Acids pharmacology, Arrestins metabolism, CHO Cells, Calcium metabolism, Cannabidiol analogs & derivatives, Cricetulus, Cyclohexanes pharmacology, Dronabinol pharmacology, Glycine analogs & derivatives, Glycine pharmacology, HEK293 Cells, Humans, Mitogen-Activated Protein Kinase 1 metabolism, Mitogen-Activated Protein Kinase 3 metabolism, Receptors, G-Protein-Coupled metabolism, Resorcinols pharmacology, Signal Transduction, beta-Arrestins, Cannabinoid Receptor Agonists pharmacology, Receptors, G-Protein-Coupled agonists
- Abstract
Background and Purpose: GPR18 is a candidate cannabinoid receptor, but its classification as such is controversial. The rationale of the study presented herein was to consider the effects of N-arachidonoyl glycine (NAGly) and cannabinoids via differential G-protein coupled pathways, in addition to β-arrestin signalling. Cellular localization of GPR18 receptors was also examined., Experimental Approach: Calcium mobilization and ERK1/2 phosphorylation were quantified in a cell line stably expressing GPR18 (HEK293/GPR18 cells). In addition, using the DiscoveRx PathHunter CHO-K1 GPR18 β-arrestin cell line, recruitment of β-arrestin was quantified., Key Results: Concentration-dependent increases in intracellular calcium and ERK1/2 phosphorylation were observed in the presence of NAGly, abnormal cannabidiol (AbnCBD), O-1602, O-1918 and Δ(9)-tetrahydrocannabinol (Δ(9)-THC) in HEK293/GPR18 cells. The initial rise in intracellular calcium in the presence of NAGly, O1918 and THC was blocked by either Gα(q) or Gα(i/o) inhibition. The ERK1/2 phosphorylation was inhibited by Pertussis toxin and N-arachidonoyl-L-serine (NARAS). Recruitment of β-arrestin in the PathHunter CHO-K1 GPR18 cell line revealed a differential pattern of GPR18 activation; of all the ligands tested, only Δ(9)-THC produced a concentration-dependent response. The localization of GPR18 receptors within the HEK293/GPR18 cells is both intracellular, and on the plasma membrane., Conclusions and Implications: These findings suggest that GPR18 activation involves several signal transduction pathways indicative of biased agonism, thereby providing a plausible explanation for the apparent discrepancies in GPR18 activation found in the literature. Additionally, the results presented herein provide further evidence for GPR18 as a candidate cannabinoid receptor., (© 2014 The British Pharmacological Society.)
- Published
- 2014
- Full Text
- View/download PDF
41. Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling.
- Author
-
Shore DM, Baillie GL, Hurst DH, Navas F 3rd, Seltzman HH, Marcu JP, Abood ME, Ross RA, and Reggio PH
- Subjects
- Allosteric Regulation drug effects, Allosteric Regulation genetics, Binding Sites, Cannabinoid Receptor Antagonists chemistry, HEK293 Cells, Humans, Indoles chemistry, Piperidines chemistry, Protein Binding, Pyrazoles, Receptor, Cannabinoid, CB1 metabolism, Rimonabant, Signal Transduction genetics, Cannabinoid Receptor Antagonists pharmacology, Indoles pharmacology, Molecular Dynamics Simulation, Piperidines pharmacology, Receptor, Cannabinoid, CB1 agonists, Receptor, Cannabinoid, CB1 antagonists & inhibitors, Signal Transduction drug effects
- Abstract
The cannabinoid 1 (CB1) allosteric modulator, 5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide) (ORG27569), has the paradoxical effect of increasing the equilibrium binding of [(3)H](-)-3-[2-hydroxyl-4-(1,1-dimethylheptyl)phenyl]-4-[3-hydroxylpropyl]cyclohexan-1-ol (CP55,940, an orthosteric agonist) while at the same time decreasing its efficacy (in G protein-mediated signaling). ORG27569 also decreases basal signaling, acting as an inverse agonist for the G protein-mediated signaling pathway. In ligand displacement assays, ORG27569 can displace the CB1 antagonist/inverse agonist, N-(piperidiny-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide(SR141716A). The goal of this work was to identify the binding site of ORG27569 at CB1. To this end, we used computation, synthesis, mutation, and functional studies to identify the ORG27569-binding site in the CB1 TMH3-6-7 region. This site is consistent with the results of K3.28(192)A, F3.36(200)A, W5.43(279)A, W6.48(356)A, and F3.25(189)A mutation studies, which revealed the ORG27569-binding site overlaps with our previously determined binding site of SR141716A but extends extracellularly. Additionally, we identified a key electrostatic interaction between the ORG27569 piperidine ring nitrogen and K3.28(192) that is important for ORG27569 to act as an inverse agonist. At this allosteric site, ORG27569 promotes an intermediate conformation of the CB1 receptor, explaining ORG27569's ability to increase equilibrium binding of CP55,940. This site also explains ORG27569's ability to antagonize the efficacy of CP55,940 in three complementary ways. 1) ORG27569 sterically blocks movements of the second extracellular loop that have been linked to receptor activation. 2) ORG27569 sterically blocks a key electrostatic interaction between the third extracellular loop residue Lys-373 and D2.63(176). 3) ORG27569 packs against TMH6, sterically hindering movements of this helix that have been shown to be important for receptor activation.
- Published
- 2014
- Full Text
- View/download PDF
42. Crucial positively charged residues for ligand activation of the GPR35 receptor.
- Author
-
Zhao P, Lane TR, Gao HG, Hurst DP, Kotsikorou E, Le L, Brailoiu E, Reggio PH, and Abood ME
- Subjects
- Amino Acid Substitution, Binding Sites, Cell Line, Humans, Ligands, MAP Kinase Signaling System genetics, Mitogen-Activated Protein Kinase 1 chemistry, Mitogen-Activated Protein Kinase 1 genetics, Mitogen-Activated Protein Kinase 1 metabolism, Mitogen-Activated Protein Kinase 3 chemistry, Mitogen-Activated Protein Kinase 3 genetics, Mitogen-Activated Protein Kinase 3 metabolism, Mutation, Missense, Phosphodiesterase Inhibitors chemistry, Protein Structure, Secondary, Purinones chemistry, Receptors, G-Protein-Coupled chemistry, Receptors, G-Protein-Coupled genetics, MAP Kinase Signaling System drug effects, Molecular Dynamics Simulation, Phosphodiesterase Inhibitors pharmacology, Purinones pharmacology, Receptors, G-Protein-Coupled metabolism
- Abstract
GPR35 is a G protein-coupled receptor expressed in the immune, gastrointestinal, and nervous systems in gastric carcinomas and is implicated in heart failure and pain perception. We investigated residues in GPR35 responsible for ligand activation and the receptor structure in the active state. GPR35 contains numerous positively charged amino acids that face into the binding pocket that cluster in two distinct receptor regions, TMH3-4-5-6 and TMH1-2-7. Computer modeling implicated TMH3-4-5-6 for activation by the GPR35 agonists zaprinast and pamoic acid. Mutation results for the TMH1-2-7 region of GPR35 showed no change in ligand efficacies at the K1.32A, R2.65A, R7.33A, and K7.40A mutants. However, mutation of arginine residues in the TMH3-4-5-6 region (R4.60, R6.58, R3.36, R(164), and R(167) in the EC2 loop) had effects on signaling for one or both agonists tested. R4.60A resulted in a total ablation of agonist-induced activation in both the β-arrestin trafficking and ERK1/2 activation assays. R6.58A increased the potency of zaprinast 30-fold in the pERK assay. The R(167)A mutant decreased the potency of pamoic acid in the β-arrestin trafficking assay. The R(164)A and R(164)L mutants decreased potencies of both agonists. Similar trends for R6.58A and R(167)A were observed in calcium responses. Computer modeling showed that the R6.58A mutant has additional interactions with zaprinast. R3.36A did not express on the cell surface but was trapped in the cytoplasm. The lack of surface expression of R3.36A was rescued by a GPR35 antagonist, CID2745687. These results clearly show that R4.60, R(164), R(167), and R6.58 play crucial roles in the agonist initiated activation of GPR35.
- Published
- 2014
- Full Text
- View/download PDF
43. Functional interaction between HIV-gp120 and opioid system in the preoptic anterior hypothalamus.
- Author
-
Palma J, Abood ME, Barbe MF, and Benamar K
- Subjects
- Animals, Fever chemically induced, Fever metabolism, Hypothalamus, Anterior drug effects, Male, Preoptic Area drug effects, Rats, Rats, Sprague-Dawley, Receptors, Opioid, mu antagonists & inhibitors, HIV Envelope Protein gp120 physiology, HIV Envelope Protein gp120 toxicity, Hypothalamus, Anterior metabolism, Narcotic Antagonists pharmacology, Preoptic Area metabolism, Receptors, Opioid, mu physiology
- Abstract
Background: Recently we found that fever (part of HIV-related wasting) is induced by the action of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein (gp120) in the preoptic anterior hypothalamus (POAH). As the opioid system plays a role in the pathogenesis of HIV-1, in the present study we sought to examine the capacity of the opioid system to regulate the febrile response induced by gp120., Methods: Stainless steel cannulas were stereotactically into the POAH, and a biotelemetry system was used to monitor the body temperature (Tb changes). We examined the in vivo effects of naloxone as well as highly opioid-selective receptor antagonists, on gp120-induced fever., Results: Pretreatment with naloxone or the mu-opioid receptor-selective antagonist, cyclic d-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH(2) (CTAP), significantly delayed the febrile response induced by gp120. In contrast, naltriben (NTB), a selective antagonist for the delta-2 opioid receptor, did not cause any effect on gp120-induced fever., Conclusion: These results (1) provide pharmacologic evidence of a functional in vivo interaction between the opioid system and this viral protein in the POAH and (2) show that mu-opioid receptors can regulate gp120-induced fever., (Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
44. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands.
- Author
-
Kotsikorou E, Sharir H, Shore DM, Hurst DP, Lynch DL, Madrigal KE, Heynen-Genel S, Milan LB, Chung TD, Seltzman HH, Bai Y, Caron MG, Barak LS, Croatt MP, Abood ME, and Reggio PH
- Subjects
- Binding Sites, Humans, Inhibitory Concentration 50, Ligands, Models, Molecular, Protein Binding, Receptors, Cannabinoid, Receptors, G-Protein-Coupled metabolism, Drug Evaluation, Preclinical, Receptors, G-Protein-Coupled antagonists & inhibitors, Receptors, G-Protein-Coupled chemistry
- Abstract
GPR55 is a class A G protein-coupled receptor (GPCR) that has been implicated in inflammatory pain, neuropathic pain, metabolic disorder, bone development, and cancer. Initially deorphanized as a cannabinoid receptor, GPR55 has been shown to be activated by non-cannabinoid ligands such as l-α-lysophosphatidylinositol (LPI). While there is a growing body of evidence of physiological and pathophysiological roles for GPR55, the paucity of specific antagonists has limited its study. In collaboration with the Molecular Libraries Probe Production Centers Network initiative, we identified a series of GPR55 antagonists using a β-arrestin, high-throughput, high-content screen of ~300000 compounds. This screen yielded novel, GPR55 antagonist chemotypes with IC50 values in the range of 0.16-2.72 μM [Heynen-Genel, S., et al. (2010) Screening for Selective Ligands for GPR55: Antagonists (ML191, ML192, ML193) (Bookshelf ID NBK66153; PMID entry 22091481)]. Importantly, many of the GPR55 antagonists were completely selective, with no agonism or antagonism against GPR35, CB1, or CB2 up to 20 μM. Using a model of the GPR55 inactive state, we studied the binding of an antagonist series that emerged from this screen. These studies suggest that GPR55 antagonists possess a head region that occupies a horizontal binding pocket extending into the extracellular loop region, a central ligand portion that fits vertically in the receptor binding pocket and terminates with a pendant aromatic or heterocyclic ring that juts out. Both the region that extends extracellularly and the pendant ring are features associated with antagonism. Taken together, our results provide a set of design rules for the development of second-generation GPR55 selective antagonists.
- Published
- 2013
- Full Text
- View/download PDF
45. Differential activation of cultured neonatal cardiomyocytes by plasmalemmal versus intracellular G protein-coupled receptor 55.
- Author
-
Yu J, Deliu E, Zhang XQ, Hoffman NE, Carter RL, Grisanti LA, Brailoiu GC, Madesh M, Cheung JY, Force T, Abood ME, Koch WJ, Tilley DG, and Brailoiu E
- Subjects
- Animals, Animals, Newborn, Cells, Cultured, Organelles metabolism, Rats, Rats, Sprague-Dawley, Myocytes, Cardiac metabolism, Receptors, Cannabinoid physiology, Receptors, G-Protein-Coupled physiology
- Abstract
The L-α-lysophosphatidylinositol (LPI)-sensitive receptor GPR55 is coupled to Ca(2+) signaling. Low levels of GPR55 expression in the heart have been reported. Similar to other G protein-coupled receptors involved in cardiac function, GPR55 may be expressed both at the sarcolemma and intracellularly. Thus, to explore the role of GPR55 in cardiomyocytes, we used calcium and voltage imaging and extracellular administration or intracellular microinjection of GPR55 ligands. We provide the first evidence that, in cultured neonatal ventricular myocytes, LPI triggers distinct signaling pathways via GPR55, depending on receptor localization. GPR55 activation at the sarcolemma elicits, on one hand, Ca(2+) entry via L-type Ca(2+) channels and, on the other, inositol 1,4,5-trisphosphate-dependent Ca(2+) release. The latter signal is further amplified by Ca(2+)-induced Ca(2+) release via ryanodine receptors. Conversely, activation of GPR55 at the membrane of intracellular organelles promotes Ca(2+) release from acidic-like Ca(2+) stores via the endolysosomal NAADP-sensitive two-pore channels. This response is similarly enhanced by Ca(2+)-induced Ca(2+) release via ryanodine receptors. Extracellularly applied LPI produces Ca(2+)-independent membrane depolarization, whereas the Ca(2+) signal induced by intracellular microinjection of LPI converges to hyperpolarization of the sarcolemma. Collectively, our findings point to GPR55 as a novel G protein-coupled receptor regulating cardiac function at two cellular sites. This work may serve as a platform for future studies exploring the potential of GPR55 as a therapeutic target in cardiac disorders.
- Published
- 2013
- Full Text
- View/download PDF
46. Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2.
- Author
-
Marcu J, Shore DM, Kapur A, Trznadel M, Makriyannis A, Reggio PH, and Abood ME
- Subjects
- Amino Acid Sequence, Benzoxazines pharmacology, Binding, Competitive drug effects, Cell Line, Cyclohexanols pharmacology, Energy Metabolism drug effects, Guanosine 5'-O-(3-Thiotriphosphate) metabolism, Humans, Immunosuppressive Agents pharmacology, Models, Chemical, Molecular Sequence Data, Morpholines pharmacology, Mutagenesis, Site-Directed, Naphthalenes pharmacology, Piperidines metabolism, Protein Conformation, Protein Structure, Secondary, Pyrazoles metabolism, Radioligand Assay, Receptor, Cannabinoid, CB1 agonists, Receptor, Cannabinoid, CB1 antagonists & inhibitors, Rimonabant, Signal Transduction drug effects, Receptor, Cannabinoid, CB1 drug effects
- Abstract
Activation of the cannabinoid CB1 receptor (CB1) is modulated by aspartate residue D2.63(176) in transmembrane helix (TMH) 2. Interestingly, D2.63 does not affect the affinity for ligand binding at the CB1 receptor. Studies in class A G protein-coupled receptors have suggested an ionic interaction between residues of TMH2 and 7. In this report, modeling studies identified residue K373 in the extracellular-3 (EC-3) loop in charged interactions with D2.63. We investigated this possibility by performing reciprocal mutations and biochemical studies. D2.63(176)A, K373A, D2.63(176)A-K373A, and the reciprocal mutant with the interacting residues juxtaposed D2.63(176)K-K373D were characterized using radioligand binding and guanosine 5'-3-O-(thio)triphosphate functional assays. None of the mutations resulted in a significant change in the binding affinity of N-(piperidiny-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride (SR141716A) or (-)-3cis -[2-hydroxyl-4-(1,1-dimethyl-heptyl)phenyl]-trans-4-[3-hydroxyl-propyl] cyclohexan-1-ol (CP55,940). Modeling studies indicated that binding-site interactions and energies of interaction for CP55,940 were similar between wild-type and mutant receptors. However, the signaling of CP55,940, and (R)-(+)-[2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]-pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl](1-naphthalenyl)-methanone mesylate (WIN55,212-2) was impaired at the D2.63(176)A-K373A and the single-alanine mutants. In contrast, the reciprocal D2.63(176)K-K373D mutant regained function for both CP55,940 and WIN55,212-2. Computational results indicate that the D2.63(176)-K373 ionic interaction strongly influences the conformation(s) of the EC-3 loop, providing a structure-based rationale for the importance of the EC-3 loop to signal transduction in CB1. The putative ionic interaction results in the EC-3 loop pulling over the top (extracellular side) of the receptor; this EC-3 loop conformation may serve protective and mechanistic roles. These results suggest that the ionic interaction between D2.63(176) and K373 is important for CB1 signal transduction.
- Published
- 2013
- Full Text
- View/download PDF
47. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors.
- Author
-
Zhao P and Abood ME
- Subjects
- Animals, Cannabinoids pharmacology, Cannabinoids therapeutic use, Gene Expression, Humans, Ligands, Receptors, Cannabinoid drug effects, Receptors, Cannabinoid genetics, Receptors, G-Protein-Coupled biosynthesis, Receptors, G-Protein-Coupled drug effects, Receptors, G-Protein-Coupled genetics, Receptors, Lysophospholipid drug effects, Receptors, Lysophospholipid genetics, Receptors, Cannabinoid physiology, Receptors, G-Protein-Coupled physiology, Receptors, Lysophospholipid physiology
- Abstract
This review presents a summary of what is known about the G-protein coupled receptors GPR35 and GPR55 and their potential characterization as lysophospholipid or cannabinoid receptors, respectively. Both GPR35 and GPR55 have been implicated as important targets in pain and cancer, and additional diseases as well. While kynurenic acid was suggested to be an endogenous ligand for GPR35, so was 2-arachidonoyl lysophosphatidic acid (LPA). Similarly, GPR55 has been suggested to be a cannabinoid receptor, but is quite clearly also a receptor for lysophosphatidylinositol. Interestingly, 2-arachidonyl glycerol (2-AG), an endogenous ligand for cannabinoid receptors, can be metabolized to 2-arachidonoyl LPA through the action of a monoacylglycerol kinase; the reverse reaction has also been demonstrated. Thus, it appears that mutual interconversion is possible between 2-arachidonoyl LPA and 2-AG within a cell, though the direction of the reaction may be site-dependent. The GPR55 natural ligand, 2-arachidonoyl LPI, can be degraded either to 2-AG by phospholipase C or to 2-arachidonoyl LPA by phospholipase D. Thus, GPR35, GPR55 and CB receptors are linked together through their natural ligand conversions. Additional agonists and antagonists have been identified for both GPR35 and GPR55, which will facilitate the future study of these receptors with respect to their physiological function. Potential therapeutic targets include pain, cancer, metabolic diseases and drug addiction., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
48. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.
- Author
-
Baillie GL, Horswill JG, Anavi-Goffer S, Reggio PH, Bolognini D, Abood ME, McAllister S, Strange PG, Stephens GJ, Pertwee RG, and Ross RA
- Subjects
- Animals, Arrestins metabolism, Benzoxazines pharmacology, Brain drug effects, Brain metabolism, CHO Cells, Cell Line, Cell Membrane drug effects, Cell Membrane metabolism, Colforsin pharmacology, Cricetinae, Cyclic AMP metabolism, Cyclohexanols pharmacology, Guanosine 5'-O-(3-Thiotriphosphate) pharmacology, HEK293 Cells, Humans, Indoles pharmacology, Kinetics, Ligands, MAP Kinase Signaling System drug effects, Male, Mice, Morpholines pharmacology, Naphthalenes pharmacology, Phosphorylation drug effects, Piperidines pharmacology, Protein Binding drug effects, Signal Transduction drug effects, beta-Arrestins, Allosteric Regulation drug effects, Receptor, Cannabinoid, CB1 agonists, Receptor, Cannabinoid, CB1 metabolism
- Abstract
We have previously identified allosteric modulators of the cannabinoid CB(1) receptor (Org 27569, PSNCBAM-1) that display a contradictory pharmacological profile: increasing the specific binding of the CB(1) receptor agonist [(3)H]CP55940 but producing a decrease in CB(1) receptor agonist efficacy. Here we investigated the effect one or both compounds in a broad range of signaling endpoints linked to CB(1) receptor activation. We assessed the effect of these compounds on CB(1) receptor agonist-induced [(35)S]GTPγS binding, inhibition, and stimulation of forskolin-stimulated cAMP production, phosphorylation of extracellular signal-regulated kinases (ERK), and β-arrestin recruitment. We also investigated the effect of these allosteric modulators on CB(1) agonist binding kinetics. Both compounds display ligand dependence, being significantly more potent as modulators of CP55940 signaling as compared with WIN55212 and having little effect on [(3)H]WIN55212 binding. Org 27569 displays biased antagonism whereby it inhibits: agonist-induced guanosine 5'-O-(3-[(35)S]thio)triphosphate ([(35)S]GTPγS) binding, simulation (Gα(s)-mediated), and inhibition (Gα(i)-mediated) of cAMP production and β-arrestin recruitment. In contrast, it acts as an enhancer of agonist-induced ERK phosphorylation. Alone, the compound can act also as an allosteric agonist, increasing cAMP production and ERK phosphorylation. We find that in both saturation and kinetic-binding experiments, the Org 27569 and PSNCBAM-1 appeared to influence only orthosteric ligand maximum occupancy rather than affinity. The data indicate that the allosteric modulators share a common mechanism whereby they increase available high-affinity CB(1) agonist binding sites. The receptor conformation stabilized by the allosterics appears to induce signaling and also selectively traffics orthosteric agonist signaling via the ERK phosphorylation pathway.
- Published
- 2013
- Full Text
- View/download PDF
49. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
- Author
-
Sharir H, Console-Bram L, Mundy C, Popoff SN, Kapur A, and Abood ME
- Subjects
- Animals, Arrestins metabolism, CHO Cells, Cell Line, Cell Survival drug effects, Cricetinae, Cricetulus, Green Fluorescent Proteins metabolism, HEK293 Cells, Humans, Immunohistochemistry, L-Lactate Dehydrogenase metabolism, Microscopy, Confocal, RNA genetics, RNA isolation & purification, Real-Time Polymerase Chain Reaction, Receptor, Cannabinoid, CB1 drug effects, Receptor, Cannabinoid, CB2 drug effects, Receptors, Cannabinoid, Receptors, G-Protein-Coupled antagonists & inhibitors, beta-Arrestins, Arachidonic Acids pharmacology, Cannabinoid Receptor Agonists pharmacology, Cannabinoid Receptor Modulators pharmacology, Cannabinoids pharmacology, Endocannabinoids pharmacology, Polyunsaturated Alkamides pharmacology, Receptors, G-Protein-Coupled drug effects
- Abstract
The role of cannabinoid receptors in inflammation has been the topic of many research endeavors. Despite this effort, to date the involvement of the endocannabinoid system (ECS) in inflammation remains obscure. The ambiguity of cannabinoid involvement may be explained by the existence of cannabinoid receptors, other than CB(1) and CB(2), or a consequence of interaction of endocannabinoids with other signaling systems. GPR55 has been proposed to be a cannabinoid receptor; however the interaction of the endocannabinoid system with GPR55 remains elusive. Consequently this study set about to examine the effects of the endocannabinoids, anandamide (AEA) and virodhamine, on GPR55 mediated signaling. Specifically, we assessed changes in β-arrestin2 (βarr2) distribution and GPR55 receptor internalization following activation by lysophosphatidylinositol (LPI), the synthetic cannabinoid ligand SR141716A, and new selective synthetic GPR55 agonists. Data obtained from the experiments presented herein demonstrate that AEA and virodhamine modulate agonist-mediated recruitment of βarr2. AEA and virodhamine act as partial agonists; enhancing the agonist effect at low concentrations and inhibiting it at high concentrations. Furthermore, both virodhamine and AEA significantly attenuated agonist-induced internalization of GPR55. These effects are attributed to the expression of GPR55, and not CB(1) and CB(2) receptors, as we have established negligible expression of CB(1) and CB(2) in these GPR55-transfected U2OS cells. The identification of select endocannabinoids as GPR55 modulators will aide in elucidating the function of GPR55 in the ECS.
- Published
- 2012
- Full Text
- View/download PDF
50. Cannabinoid receptors: nomenclature and pharmacological principles.
- Author
-
Console-Bram L, Marcu J, and Abood ME
- Subjects
- Animals, Brain drug effects, Brain metabolism, Cannabinoids pharmacology, Signal Transduction drug effects, Signal Transduction physiology, Cannabinoids metabolism, Polymorphism, Genetic, Receptors, Cannabinoid genetics, Receptors, Cannabinoid metabolism, Terminology as Topic
- Abstract
The CB1 and CB2 cannabinoid receptors are members of the G protein-coupled receptor (GPCR) family that are pharmacologically well defined. However, the discovery of additional sites of action for endocannabinoids as well as synthetic cannabinoid compounds suggests the existence of additional cannabinoid receptors. Here we review this evidence, as well as the current nomenclature for classifying a target as a cannabinoid receptor. Basic pharmacological definitions, principles and experimental conditions are discussed in order to place in context the mechanisms underlying cannabinoid receptor activation. Constitutive (agonist-independent) activity is observed with the overexpression of many GPCRs, including cannabinoid receptors. Allosteric modulators can alter the pharmacological responses of cannabinoid receptors. The complex molecular architecture of each of the cannabinoid receptors allows for a single receptor to recognize multiple classes of compounds and produce an array of distinct downstream effects. Natural polymorphisms and alternative splice variants may also contribute to their pharmacological diversity. As our knowledge of the distinct differences grows, we may be able to target select receptor conformations and their corresponding pharmacological responses. Importantly, the basic biology of the endocannabinoid system will continue to be revealed by ongoing investigations., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.